Brief: Camurus Announces Expansion Of Lilly Collaboration
01/06/2026 16:04
BRIEF-Camurus Announces Expansion Of Lilly Collaboration June 1 (Reuters) - Camurus AB CAMX.ST:
CAMURUS ANNOUNCES EXPANSION OF LILLY COLLABORATION
ELI LILLY EXERCISES OPTION TO INCLUDE AMYLIN RECEPTOR AGONISTS IN CAMURUS COLLABORATION
AGREEMENT COVERS UP TO FOUR LILLY DRUG COMPOUNDS ACROSS THREE CLASSES
LILLY'S EXCLUSIVE GLOBAL RIGHTS TO FLUIDCRYSTAL TECHNOLOGY EXTENDED TO ADDITIONAL COMPOUND CLASS
ELIGIBLE FOR UP TO $290 MILLION UPFRONT, $580 MILLION SALES MILESTONES, PLUS ROYALTIES
OPTION EXERCISE TRIGGERS $5 MILLION INITIAL PAYMENT TO CAMURUS
Source text: ID:nWkr6FZcvJ
Further company coverage: CAMX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Camurus AB
See all newsBrief: Camurus Receives Approval In Canada For Oczyesa XR
Brief: Executive Sells About £279,000 Of Camurus Shares
Jefferies cuts Ipsen to 'underperform' on Somatuline competition risk
Brief: Camurus Says NDA Resubmission For CAM2029 In Acromegaly Accepted For Review By FDA
Camurus shares rise after Q2 revenue, operating profit beat